Senior commercial executives of Trinity Biotech plc will attend the World Health Expo from February 10-12, 2026. The company will showcase innovations in diabetes management, including its Premier Hb9210™ HbA1c Analyser, which recently achieved the prestigious Gold Classification from the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) for 2026. For more information about Trinity Biotech and the Premier Hb9210™ system, interested parties can contact info@trinitybiotech.com.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Trinity Biotech plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001178913-26-000469), on February 13, 2026, and is solely responsible for the information contained therein.